Pirquinozol (SQ-13,847) is a drug which was investigated as an antiallergen and antiasthmatic agent in the early 1980s but was never marketed.[1][2][3] Notably, pirquinozol is not an antihistamine, though it does block the release of histamine evoked by allergens, and it does not bind to β-adrenergic receptors either.[1]

Pirquinozol
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 2-(hydroxymethyl)pyrazolo[1,5-c]quinazolin-5(6H)-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H9N3O2
Molar mass215.212 g·mol−1
3D model (JSmol)
  • OCc1cc2c3ccccc3NC(=O)n2n1

References

edit
  1. ^ a b Free CA, Hall LE (June 1980). "Antiallergic properties of SQ 13,847, an orally effective agent. II. Activity in vitro". The Journal of Pharmacology and Experimental Therapeutics. 213 (3): 437–40. PMID 6162946.
  2. ^ Casey FB, Abboa-Offei BE, Marretta J (June 1980). "Antiallergic properties of SQ 13,847, an orally effective agent. I. Activity in vivo". The Journal of Pharmacology and Experimental Therapeutics. 213 (3): 432–6. PMID 7205610.
  3. ^ Casey FB, Abboa-Offei BE (June 1983). "Anti-allergic properties of pirquinozol (SQ 13,847) an orally effective agent. Evaluation in an anti-IgE-induced pulmonary function model in rats". The Journal of Pharmacy and Pharmacology. 35 (6): 394–6. doi:10.1111/j.2042-7158.1983.tb02967.x. PMID 6135784. S2CID 7790125.